Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

BACKGROUND: Development of acquired resistance limits the utility of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR mutant lung cancers. There are no accepted, targeted therapies for use after acquired resistance develops. Metastasectomy is used in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yu, Helena A., Sima, Camelia S., Huang, James, Solomon, Stephen B., Rimner, Andreas, Paik, Paul, Pietanza, M. Catherine, Azzoli, Christopher G., Rizvi, Naiyer A., Krug, Lee M., Miller, Vincent A., Kris, Mark G., Riely, Gregory J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3673295/
https://ncbi.nlm.nih.gov/pubmed/23407558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31827e1f83
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados